Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for three more years to discover novel small molecule therapeutics. No financial details were disclosed.
 
The collaboration began in May 2010 and was renewed in 2013. Evotec provides pharmacology, screening, chemistry, proteomics and structural biology services using its technology platform and drug discovery expertise.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are delighted that once again we have extended this fruitful collaboration beyond its 7th year and this latest extension is validation of the value Evotec brings to this partnership. With an increasing portfolio of activities, the scientific teams from both companies are working closely together to effectively and efficiently advance Genentech’s discovery projects.”